Quantinno Capital Management LP Increases Position in Medline $MDLN

Posted by Brian Himes on Aug 12th, 2026

Quantinno Capital Management LP grew its position in Medline (NASDAQ:MDLN – Free Report) by 91.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,739 shares of the company’s stock after purchasing an additional 21,837 shares during the quarter. Quantinno Capital Management LP’s holdings in Medline were worth $2,035,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Mass General Brigham Inc purchased a new stake in Medline during the 4th quarter worth about $1,104,000. Sumitomo Mitsui Trust Group Inc. acquired a new position in shares of Medline during the 1st quarter worth about $1,177,000. Cetera Investment Advisers increased its holdings in shares of Medline by 128.4% in the 1st quarter. Cetera Investment Advisers now owns 52,088 shares of the company’s stock valued at $2,318,000 after acquiring an additional 29,282 shares during the last quarter. UBS Group AG purchased a new position in shares of Medline in the 4th quarter valued at about $54,707,000. Finally, Pictet Asset Management Holding SA acquired a new stake in shares of Medline during the 4th quarter worth about $48,996,000.

Insider Activity

In related news, major shareholder Private Ltd Gic sold 590,284 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $35.58, for a total value of $21,002,304.72. Following the transaction, the insider owned 24,402,482 shares in the company, valued at $868,240,309.56. The trade was a 2.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jessi L. Corcoran acquired 5,000 shares of Medline stock in a transaction on Friday, June 5th. The shares were bought at an average cost of $34.15 per share, with a total value of $170,750.00. Following the completion of the purchase, the insider owned 5,000 shares in the company, valued at $170,750. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders sold 2,938,896 shares of company stock valued at $104,656,454. Insiders own 0.81% of the company’s stock.

Medline Stock Performance

Shares of Medline stock opened at $35.04 on Wednesday. The firm’s fifty day simple moving average is $38.21 and its 200-day simple moving average is $41.57. Medline has a 12 month low of $32.81 and a 12 month high of $50.88. The stock has a market capitalization of $46.03 billion and a price-to-earnings ratio of 109.50. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.33 and a quick ratio of 2.61.

Medline (NASDAQ:MDLN – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.18. The business had revenue of $7.68 billion for the quarter. As a group, equities analysts forecast that Medline will post 1.49 earnings per share for the current year.

Medline News Roundup

Here are the key news stories impacting Medline this week:

Positive Sentiment: TD Cowen maintained a Buy rating and set a $45 price target, implying substantial upside from recent levels. The firm cited Medline’s strong cash flow and longer-term growth outlook. TD Cowen Medline rating
Positive Sentiment: Tigress Financial lowered its price target from $62 to $55 but retained a Buy rating. The revised target still represents significant potential upside, suggesting the analyst views recent weakness as excessive. Benzinga analyst action
Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day short-interest ratio. Because the figures include an apparent “NaN” calculation, the data may be incomplete or unreliable and offers little actionable insight for investors.
Negative Sentiment: Wells Fargo cut its price target from $45 to $34 and changed its stance to Equal Weight. The new target is slightly below the recent trading level, signaling limited near-term upside in the firm’s view. Wells Fargo Medline price target
Negative Sentiment: Major shareholder Private Ltd Gic sold approximately 590,284 shares worth $21.0 million, reducing its ownership by 2.36%. While the investor still holds a substantial stake, the sale may add modest pressure or raise concerns about insider sentiment. SEC ownership filing
Negative Sentiment: Law firm Kaplan Fox announced an investigation into potential securities-law violations involving Medline. The announcement does not establish wrongdoing, but it introduces legal and reputational risk and may weigh on investor confidence. Kaplan Fox Medline investigation

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MDLN. Stifel Nicolaus lowered their price target on Medline from $50.00 to $45.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Citigroup raised shares of Medline to a “strong-buy” rating in a report on Wednesday, August 5th. Truist Financial reduced their price objective on shares of Medline from $56.00 to $47.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. BTIG Research restated a “buy” rating and issued a $55.00 target price on shares of Medline in a report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft set a $37.00 target price on shares of Medline in a research report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $47.69.

Check Out Our Latest Stock Report on MDLN

Medline Profile

(Free Report)

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.